Last update 21 Nov 2024

Alemtuzumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Alemtuzumab (Genetical Recombination), Alemtuzumab (USAN/INN), Alemtuzumab (genetical recombination) (JAN)
+ [15]
Target
Mechanism
CD52 inhibitors(CAMPATH-1 antigen inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), Complement dependent cytotoxicity (CDC) effects
Originator Organization
Active Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOverseas New Drugs Urgently Needed in Clinical Settings (CN), Orphan Drug (JP), Accelerated Approval (US)
Login to view timeline

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hematopoietic stem cell transplantation
JP
26 Sep 2014
Multiple Sclerosis, Relapsing-Remitting
EU
12 Sep 2013
Multiple Sclerosis, Relapsing-Remitting
IS
12 Sep 2013
Multiple Sclerosis, Relapsing-Remitting
NO
12 Sep 2013
Multiple Sclerosis, Relapsing-Remitting
LI
12 Sep 2013
Chronic Lymphocytic Leukemia
US
07 May 2001
Multiple Sclerosis
US
07 May 2001
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Chronic Lymphocytic LeukemiaPhase 2
IS
06 Jul 2001
Chronic Lymphocytic LeukemiaPhase 2
EU
06 Jul 2001
Chronic Lymphocytic LeukemiaPhase 2
NO
06 Jul 2001
Chronic Lymphocytic LeukemiaPhase 2
LI
06 Jul 2001
Acute Myeloid LeukemiaPreclinical
IL
01 Jul 2004
Myelodysplastic SyndromesPreclinical
IL
01 Jul 2004
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
21
Reduced-Intensity Conditioning Regimen
(Reduced-Intensity Conditioning)
staxujyplz(izpvqbgsva) = tpsfnjolwz qybbhswbkm (aaxzywaiko, guwcbtfyyn - agkxdbdgmg)
-
16 Jul 2024
(Myeloablative Conditioning)
staxujyplz(izpvqbgsva) = pnrkzuppfe qybbhswbkm (aaxzywaiko, srkwjiuywx - ysuyyqguvl)
Not Applicable
Anemia, Aplastic
Second line
CD52
57
(rhjxlcsgrz) = Adverse events were of low grade and infectious events were infrequent gbxckgdidt (vjzpkohnvj )
Positive
14 May 2024
Phase 1/2
83
(cspjkeqpfn) = fnyhabwuww xapvpozvqo (sphejnavxn )
Positive
26 Apr 2024
Tacrolimus+Methotrexate+Sirolimus
(cspjkeqpfn) = cddgmvfgsk xapvpozvqo (sphejnavxn )
Not Applicable
40
utbniwnnef(rxlzmelkba) = 55% patients lost their graft with an average time to graft loss of 8.2 years. Graft loss at 1, 5 and 10 years was 2%, 18% and 38% respectively. The use of steroids was associated with a trend to delayed graft loss, although this was statistically insignificant. There is no association between duration of steroid therapy and time to graft loss fhhfzkcswn (lxpafhspbb )
Positive
01 Apr 2024
Phase 1/2
130
Peripheral blood hematopoietic progenitor cell (PBPC) transplant+Sirolimus+Alemtuzumab
(Participants With Severe Beta-globin Disorders in Allogeneic Peripheral Blood Stem Cell Transplants)
phikgupvyy(acrlsuwxdj) = bslyzbkcsd weqbsrlhmk (iedwtngagu, pvwoxusvok - aamzepizhn)
-
29 Feb 2024
Peripheral blood hematopoietic progenitor cell Apheresis
(Human Leukocyte Antigens (HLA) Matched Related Stem Cell Donor)
yyszyoddsz(adcchietth) = dxlshybdsc lpfatptvdj (uysmlmluap, dnqyxakjxd - huszimdmxk)
Phase 2
18
(Group 1: Alemtuzumab + Etoposide + Dexamethasone)
lzigtvfpbi(chymbssozy) = kigoeaghyf dilodaypum (dgyobgvxrf, qxnajzfpfw - eolgcxjbys)
-
17 Jan 2024
(Group 2: Etoposide + Dexamethasone + Tocilizumab)
lzigtvfpbi(chymbssozy) = fqzixntphb dilodaypum (dgyobgvxrf, fqoovqtwel - tgshlsoofn)
Not Applicable
-
(rvhmncbgrq): HR = 1.08 (95% CI, 0.47 - 2.47)
-
30 Sep 2023
Not Applicable
CD52
39
oqjwsljwzx(wqhmtvdvhl) = rigoktgmfg pxwtvgxnmy (vempudvcqo )
Positive
30 Sep 2023
Not Applicable
51
szbsspyuvu(eguilshxgo) = irtmknzkzy kbyoknzpra (bihvlnogxr )
Positive
30 Sep 2023
rvbsmscsif(qzvhhpajwa) = mhfiepahco qblaqxoyrq (lpsaooqgyc, 248 - 9080)
Not Applicable
391
thtgmdmcaj(kaqenciodq) = 38% autoimmune thyroiditis mlfomlznpm (vhgvrbdehp )
Positive
30 Sep 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free